Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Septerna (SEPN) stock in plain English

Free brief · no signupStart here
SEPNPublished Nov 16, 2026
Septerna Inc
Healthcare · Biotechnology
Develops oral small-molecule medicines targeting G protein-coupled receptors for endocrine and metabolic diseases.
Assets:
Native Complex Platformreconstitutes functional GPCR targets outside cells for drug discovery
SEP-479 drug candidateoral small-molecule therapy currently undergoing Phase 1 testing
SEP-204 programpreclinical candidate focused on treating Graves disease
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

69
OPS ScoreOperating finances
Latest quote
-0.63%$39.20
$1.86B
n/a (loss)
$96.28M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was SEPN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Septerna (SEPN) do?

Septerna Inc (SEPN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops oral small-molecule medicines targeting G protein-coupled receptors for endocrine and metabolic diseases. Recreates cell membrane receptors outside cells to discover oral small-molecule medicines targeting GPCRs. It is worth $1.86B on the market and sold $96.28M over the last year.

Market cap
$1.86B
P/E ratio
None (reported a loss)
Annual sales
$96.28M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 16, 2026

SEPN’s flags, in plain English

Each flag is a number from Septerna’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 4.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 5% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 98.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -61.3%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about SEPN

How big is Septerna?

Septerna’s market cap is $1.86B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $96.28M: what customers paid the company over the last year, before any costs.

What is SEPN’s P/E ratio?

SEPN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with SEPN?

The company generates no commercial product revenue and relies on existing cash reserves to fund drug development. That is one risk on Septerna’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Septerna’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SEPN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card